In Phase C, members will obtain ABBV-744 and oral navitoclax. In Section D, participants will obtain ABBV-744 and ruxolitinib. Contributors will obtain treatment until finally illness progression or maybe the participants are not able to tolerate the study drugs. and afterwards market H3K27Ac at